Status:
COMPLETED
Performance of AclarusDx™, a Blood-Based Transcriptomic Test for AD, in US Patients Newly Referred to a Memory Center
Lead Sponsor:
Exonhit
Conditions:
Alzheimer's Disease
Mild Cognitive Impairment
Eligibility:
All Genders
21+ years
Brief Summary
The purpose of this study is to assess the performance of AclarusDx™, an investigational blood test detecting gene expression information, and intended to help physicians in making an Alzheimer's Dise...
Detailed Description
The objective of this study is to apply AclarusDx™ signature in a reference US Center in 160 patients newly referred to one of the three study centers within the Cleveland Clinic, Center for Brain Hea...
Eligibility Criteria
Inclusion
- Male or female patient referred to the center for memory impairment.
- The memory impairment has previously been observed by a caregiver or documented by a physician.
- The memory impairment is confirmed by the memory center.
- Caucasian ethnicity.
- A written informed consent approved by an ethical review board or similar body must be obtained from the patient prior to any study-related procedures.
- If applicable, standard treatment with cholinesterase inhibitor and/or memantine is acceptable.
- Patient estimated to be compliant with study procedures.
- Patient has a level of understanding sufficient to agree to all procedures required by the protocol and must be able to cooperate. Under no circumstances will a subject who does not understand the procedure, be allowed to consent to the procedure.
Exclusion
- Recent acute pathology or medical condition or surgery which may alter the inflammatory homeostasis, according to the opinion of the investigator.
- Non-Caucasian ethnicity.
- Patient with severe uncontrolled or unstable medical condition.
- Need for a legal representative for the medical condition of the patient.
- Any current pathology or medical condition, for which blood sampling may involve a risk for the patient's health, according to the opinion of the investigator.
- Current or recent history (within one month) of clinically significant pathology, medical condition (including hospitalization) or symptoms. However, chronic diseases or medical conditions that are considered stable are accepted, provided that they are compatible with other study selection criteria.
- Current or recent history of drug or alcohol abuse or dependence.
- Current, clinically significant major psychiatric disorder (eg, major depressive disorder) according to the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition text revised (DSM-IV TR), or significant symptoms (eg, hallucinations).
- Woman of childbearing potential is not allowed to participate in the study. (A woman of childbearing potential is a woman who is biologically capable of becoming pregnant).
- Current participation in another study using an investigational non-marketed product.
Key Trial Info
Start Date :
November 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
160 Patients enrolled
Trial Details
Trial ID
NCT01465360
Start Date
November 1 2011
Last Update
July 6 2012
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Cleveland Clinic Lou Ruvo Center for Brain Health
Las Vegas, Nevada, United States, 89106
2
Cleveland Clinic Center for Brain Health - Mellen Center
Cleveland, Ohio, United States, 44195
3
Cleveland Clinic Senior Care Assessment - Lakewood Hospital
Lakewood, Ohio, United States, 44107